The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Cost of Relapse in Schizophrenia
Open accessAbstract
To estimate the national annual cost of rehospitalization for multiple-episode schizophrenia outpatients, and to determine the relative cost burden from loss of medication efficacy and from medication noncompliance, the yearly number of neuroleptic-responsive multiple-episode schizophrenia inpatients in the United States who are discharged back to outpatient treatment was estimated. The cohort at risk for future relapse and rehospitalization was determined. The research literature on the expected rates of relapse for schizophrenia patients on maintenance antipsychotic medication was reviewed; in particular, monthly relapse rates under the optimal medication conditions of compliant patients taking optimal doses of a depot neuroleptic (optimal neuroleptic dose) and under the less optimal conditions of patients stopping medication (medication noncompliant) was estimated. Using established noncompliance rates from the literature, it became possible to estimate a "real world" rehospitalization rate for this cohort, as well as the relative burden accruing from loss of medication efficacy and from medication noncompliance. Finally, cost estimates for index hospitalizations and rehospitalizations were derived from data on national expenditures for inpatient mental health care. The monthly relapse rates are estimated to be 3.5 percent per month for patients on maintenance neuroleptics and 11.0 percent per month for patients who have discontinued their medication. Postdischarge noncompliance rates in community settings are estimated to be 7.6 percent per month. These estimates were entered into a survival analysis model to determine the real world relapse rate of this cohort. An estimated 257,446 multiple-episode (> or = two hospitalizations) schizophrenia patients were discharged from short-stay (< or = 90 days) inpatient units in the United States during 1986. The estimated aggregate baseline inpatient cost for the index hospitalizations of this cohort was $2.3 billion (1993 dollars). Within 2 years after discharge, the aggregate cost of readmission approached $2 billion. Loss of neuroleptic efficacy accounted for roughly 60 percent of the rehospitalization costs and neuroleptic noncompliance for roughly 40 percent. The economic burden due to loss of efficacy is relatively higher during the first postdischarge year, whereas the burden from noncompliance is higher in the second year. Because loss of medication efficacy and medication noncompliance act synergistically on relapse, substantial inpatient cost savings can be realized by linking better pharmacologic treatments of schizophrenia with more effective strategies to manage medication noncompliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stein, L. I. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780170034003 · Cited by 1,902
Hogarty, G. E. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800070019003 · Cited by 917
Drug and Sociotherapy in the Aftercare of Schizophrenic Patients: II. Two-Year Relapse Rates
Hogarty, G. E. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760170005001 · Cited by 573
Frank, A. F. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150028006 · Cited by 552
Comparative Doses and Costs of Antipsychotic Medication
Davis, J. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770070088010 · Cited by 407
Mental Health, United States, 2002: (400052005-001)
Manderscheid, R. W., & Henderson, M. J. (2004) · PsycEXTRA Dataset · doi:10.1037/e400052005-001 · Cited by 245
Falloon, I., Watt, D. C., & Shepherd, M. (1978) · Psychological Medicine · doi:10.1017/s0033291700006632 · Cited by 196
Prevention of Relapse in Schizophrenia: An Evaluation of Fluphenazine Decanoate
Schooler, N. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140018002 · Cited by 177
Long-term Course of Hospitalization for Schizophrenia: Part I. Risk for Rehospitalization
Eaton, W. W., Mortensen, P. B., Herrman, H., Freeman, H., Bilker, W., Burgess, P., & Wooff, K. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.2.217 · Cited by 170
Compliance, quality assurance and standards for relapse prevention in schizophrenia
Kissling, W. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05860.x · Cited by 161
Temporal Effects of Drug and Placebo in Delaying Relapse in Schizophrenic Outpatients
Hogarty, G. E. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770150055005 · Cited by 160
The General Practitioner and the Schizophrenic Patient
Parkes, C. M., Brown, G. W., & Monck, E. (1962) · BMJ · doi:10.1136/bmj.1.5283.972 · Cited by 146
A FOLLOW‐UP OF SCHIZOPHRENIC PATIENTS IN EDINBURGH
Renton, C. A., Affleck, J. W., CARSTAIRS, G. M., & Forrest, A. D. (1963) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1963.tb07482.x · Cited by 145
Phenothiazines in Prevention of Psychiatric Hospitalization
Engelhardt, D. M., Rosen, B., Freedman, N., & Margolis, R. (1967) · Archives of General Psychiatry · doi:10.1001/archpsyc.1967.01730190100013 · Cited by 93
Long-term Course of Hospitalization for Schizophrenia: Part II. Change With Passage of Time
Eaton, W. W., Bilker, W. B., Haro, J. M., Herrman, H., Mortensen, P. B., Freeman, H. L., & Burgess, P. M. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.2.229 · Cited by 83
Knights, A., Okasha, M. S., Salih, M. A., & Hirsch, S. R. (1979) · The British Journal of Psychiatry · doi:10.1192/bjp.135.6.515 · Cited by 79
Measuring the Economic Costs of Schizophrenia
McGuire, T. G. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.3.375 · Cited by 74
Controlled Trial of Depot Fluphenazine in Out-patient Schizophrenics
Crawford, R. S., & Forrest, A. D. (1974) · The British Journal of Psychiatry · doi:10.1192/bjp.124.4.385 · Cited by 73
Prevention of Recidivism of Schizophrenics Treated with Fluphenazine Enanthate
del Giudice, J., Clark, W. G., & Gocka, E. F. (1975) · Psychosomatics · doi:10.1016/s0033-3182(75)71232-x · Cited by 60
The Scottish First Episode Schizophrenia Study V. One-year Follow-up
McCreadie, R. G., Wiles, D. H., Grant, S. M., MOORE, J. W., Crocket, G. T., Mahmood, Z., Livingston, M. G., Watt, J. A. G., Greene, J. G., Kershaw, P. W., et al. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.152.4.470 · Cited by 52
Neuroleptic noncompliance in schizophrenia
Weiden, P. J., Manevitz, A., Dixon, L. B., Sweeney, J. A., Haas, G. L., & FRANCES, A. J. (1989) · Schizophrenia Research · doi:10.1016/0920-9964(89)90250-8 · Cited by 51
Self-citationRelapse in schizophrenia: a review of the concept and its definitions
Falloon, I. R. H., Marshall, G. N., Boyd, J. L., Razani, J., & Wood‐Siverio, C. (1983) · Psychological Medicine · doi:10.1017/s0033291700047899 · Cited by 48
Use of survival curves in analysis of antipsychotic relapse studies.
Davis, J. M., Dysken, M. W., Haberman, S. J., Javaid, J. I., Chang, S. S., & Killian, G. A. (1980) · PubMed · Cited by 48
Effect of length of inpatient treatment for chronic schizophrenia
Caton, C. L. M. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.7.856 · Cited by 46
III. Relapse Postponement or Relapse Prevention? The Implications for Long-term Outcome
Curson, D. A., Barnes, T. R. E., Bamber, R. W., Platt, S. D., Hirsch, S. R., & Duffy, J. C. (1985) · The British Journal of Psychiatry · doi:10.1192/bjp.146.5.474 · Cited by 43
Factors Involved in Failure to Keep Initial Appointments With Mental Health Professionals
Nicholson, I. R. (1994) · Psychiatric Services · doi:10.1176/ps.45.3.276 · Cited by 33
Adjustment of Schizophrenics in the Community
Serban, G. (1980) · Springer eBooks · doi:10.1007/978-94-011-5921-0 · Cited by 19
Long‐term fluphenazine decanoate maintenance dosage requirements of chronic schizophrenic patients
Capstick, N. (1980) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1980.tb00875.x · Cited by 18
Gäebel, W., & Pietźcker, A. (1985) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00380969 · Cited by 14
Calculating the Cost of Schizophrenia
Wyatt, R. J., & Clark, K. P. (1987) · Psychiatric Annals · doi:10.3928/0048-5713-19870901-07 · Cited by 11
Cited by
How stigma interferes with mental health care.
Corrigan, P. (2004) · American Psychologist · doi:10.1037/0003-066x.59.7.614 · Cited by 3,648
Mental illness stigma: Concepts, consequences, and initiatives to reduce stigma
Rüsch, N., Angermeyer, M. C., & Corrigan, P. W. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.04.004 · Cited by 1,621
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383
Bach, P., & Hayes, S. C. (2002) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.70.5.1129 · Cited by 839
Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.886 · Cited by 621
Self-citation
Metadata
- Authors
- Weiden, P. J., & Olfson, M.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-01-01
- Volume
- 21
- Issue
- 3
- Pages
- 419-429
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2099123602
- Cited by
- 666
- References
- 30
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.